There’s a newly approved hepatitis C medication.
The Food and Drug Administration (FDA) has approved AbbVie’s once-daily Mavyret to treat all six major genotypes of hepatitis C virus (HCV).The pangenotypic tablet includes the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir.
The approval is for an eight-week regimen for those new to treatment who do not have cirrhosis or who have compensated cirrhosis (the milder form of the advanced liver disease), including those with moderate to severe chronic kidney disease and those who are on dialysis.
Mavyret, formerly known by the shorthand G/P, is also approved for those with HCV genotype 1 who were previously treated with a regimen containing either a drug from the NS5A inhibitor or the NS3/4A protease inhibitor class of direct-acting antivirals (DAAs), but not both.
The recommended treatment length depends on an individual’s past experience with hep C treatment, viral genotype and cirrhosis status.
Read full article: FDA OKs AbbVie’s Mavyret for All Hepatitis C Genotypes – Hep
|Read Full Article: FDA OKs AbbVie’s Mavyret for All Hepatitis C Genotypes – Hep|